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Modelling cost effectiveness of meningococcal serogroup
C conjugate vaccination campaign in England and Wales
Caroline L Trotter, W John Edmunds
Abstract
Objectives To assess the cost effectiveness of a
meningococcal serogroup C conjugate vaccination
campaign in 0›17 year olds.
Design Cost effectiveness analysis from the
perspective of the healthcare provider.
Setting England and Wales.
Main outcome measure Cost per life year saved.
Results In 1998›9, immediately before the
introduction of meningococcal C vaccination, the
burden of serogroup C disease was considerable, with
an estimated 1137 cases in people aged 0›17 years
and at least 72 deaths. The vaccination campaign is
estimated to have cost between £126m ($180m,
&207m) and £241m ($343m, &395m), depending on
the price of the vaccine. Under base case assumptions
the cost per life year saved from the vaccination
campaign is estimated to be £6259. School based
vaccination was more cost effective than general
practice based vaccination because of lower delivery
costs. Immunisation of infants aged under 1 year was
the least cost effective component of the campaign
because, although this maximises the life years gained,
the three dose schedule required is more expensive
than other methods of delivery. Estimates of the cost
per life year saved were sensitive to assumptions on
the future incidence of disease and the case fatality
ratio.
Conclusions Meningococcal C vaccination is likely to
be more cost effective in all age groups when the
incidence of disease is high. It is also more cost
effective when given to children aged 1›4 (by general
practitioners) and to children and young people aged
5›17 years at school than when administered to
infants under 12 months of age or young people aged
16›17 years who are not at school.
Introduction
In November 1999 the UK Department of Health
incorporated meningococcal serogroup C conjugate
(MenC) vaccine into routine infant immunisation and
launched a national campaign offering vaccine to
everyone aged under 18 years.1 The accelerated testing
and introduction of this vaccine was prompted by a
growing burden of meningococcal disease from the
mid›1990s onwards, with serogroup C becoming more
important.2 The vaccine provided a new opportunity
for primary prevention of meningococcal disease
because, unlike the older polysaccharide vaccines, it is
immunogenic in infants and primes for memory.3
We considered the cost effectiveness of the UK vac›
cination campaign in terms of the cost per life year
saved from the perspective of the healthcare provider
(the NHS). We considered only costs and savings
accruing to the NHS compared with the life years
saved. We ignored private costs and private benefits,
except loss of life.
Methods
We compared the cost effectiveness of the meningo›
coccal C vaccine campaign with the previous strategy,
when there was no national vaccination programme
and cases were treated as they arose, with control
measures implemented in the event of an outbreak.4
We compared the cost effectiveness of different
components of the UK vaccination strategy (such as
routine versus catch up, school based versus general
practitioner based immunisation).
Cohort model
Because no clinical trial of vaccine efficacy exists we
constructed a model to estimate the direct impact of
the campaign by following an imaginary vaccine cam›
paign cohort over a lifetime. This comprised 18 birth
cohorts of people aged 0›17 who were offered vaccine
in the first year of the campaign. We assumed there
were 658 800 individuals in each cohort at birth, which
is the average size of birth cohorts over the past 18
years (source: Office for National Statistics). We
calculated the number of cases of serogroup C menin›
gococcal disease per year by multiplying estimated
incidence of disease by the susceptible population. In
all cases patients were assumed to die or to acquire life›
long immunity to meningococcal disease and so were
removed from the susceptible pool. Those dying from
serogroup C meningococcal disease were assumed to
lose the average life expectancy for the age at which
they died.
Sensitivity analysis
The base case scenario was considered to be the most
likely set of parameters. However, because of
uncertainty surrounding these estimates we explored a
range of values. Firstly, we varied one parameter at a
time within its given range in a univariate sensitivity
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analysis. Secondly, we performed a multivariate
sensitivity analysis, under six different scenarios of dis›
ease burden, using Monte Carlo simulation with
@RISK 4.0 (Palisade Corporation, NY, USA) running
within Microsoft Excel. Here, we drew input parameter
values from a probability distribution using Latin
hypercube sampling. Uniform distributions were
assumed for all input parameter values in the base case.
The model was simulated 500 times to generate a dis›
tribution of outcome values.
Costs and discounting
We measured all costs in pounds sterling at 2000
prices, with costs estimated from previous years
inflated using the hospital and community health serv›
ices pay and prices index. Future costs and benefits
were discounted back to their present value, with the
assumption that all costs and benefits occurred at the
end of the year. In the base case we used a 3% discount
rate for both costs and benefits, as recommended by
the US panel.5 We investigated a range of other
discount rates because national recommendations
differ—for example, the UK Department of Health rec›
ommends discount rates of 1.5% for benefits and 6%
for costs.6
Estimating model parameters
In the base case we derived future incidence of
serogroup C disease from 1998›9 estimates because
this was the period immediately before the introduc›
tion of the vaccine. The incidence of notified and labo›
ratory confirmed meningococcal disease in the United
Kingdom had increased every year from 1995, and the
proportion of cases attributable to serogroup C
increased from 25% to almost 40%7 because of the
introduction and spread of a virulent clone (C2a, elec›
trophoretic type 15) over this time period. To explore
the effects of a lower incidence in the sensitivity analy›
sis we also estimated the average incidence of
serogroup C disease between 1989›90 and 1994›5
(table 1).
We obtained data on serogroup and age from
1989›99 from the meningococcal reference unit of the
Public Health Laboratory Service. Not all infections
are confirmed by a laboratory, and not all confirmed
cases are characterised by serogroup,8 so we adjusted
these data to estimate the true incidence of disease.
Firstly, we estimated underascertainment by compar›
ing reference unit data with hospital episode statistics
and derived scale up factors. The hospital episode sta›
tistics (www.doh.gov.uk/hes) contain details of all
patients admitted to and treated in NHS hospitals in
England and is likely to be the most complete source of
information on meningococcal disease. Cases were
classified as meningococcal disease if there were
ICD›10 (international classification of diseases, 10th
revision) codes A39.0›A39.9 in any of the seven
diagnostic fields (ICD›9 codes used before 1996).
Secondly, after 1996 (when diagnosis with the
polymerase chain reaction was widely introduced)
cases confirmed by polymerase chain reaction but
uncharacterised were proportionally redistributed
among other serogroups.
Deaths from meningococcal disease are registered
with the Office for National Statistics with ICD›9
disease specific codes; and these are routinely linked to
reference unit laboratory reports. In 1998›9 there were
72 registered deaths from laboratory confirmed
serogroup C disease in 0›17 year olds. This is a
minimum estimate as not all cases are confirmed by a
laboratory and not all deaths will be registered to codes
specific to meningococcal disease. Because of this
uncertainty we used a range of mortality estimates in
the sensitivity analysis. For the high estimate we calcu›
lated age specific case fatality ratios by dividing the
number of laboratory confirmed registered deaths by
the number of laboratory confirmed cases in 1998›9.
For the low estimate we calculated the case fatality ratio
by dividing the actual number of laboratory confirmed
registered deaths by the adjusted number of cases for
1998›9 (described above). The medium estimate, used
in the base case, was the mean of the high and low esti›
mates (table 1). The widely quoted Department of
Health estimate of 150 deaths per year (all ages) from
serogroup C disease is based on estimates of case fatal›
ity ratios from enhanced surveillance of meningococ›
cal disease,2 which are similar to our high estimate.
We assumed that in all cases of meningococcal dis›
ease patients were admitted to hospital and were
recorded in the hospital episode statistics database. We
estimated the average length of stay in hospital for spe›
cific ages from hospital episode statistics between
1997›8 and 1998›9 and the proportion of cases admit›
ted to an intensive care unit and the length of stay from
1998›9 data (fig 1). We obtained details of the cost of an
intensive care bed per day from NHS reference costs
(www.doh.gov.uk/nhsexec/refcosts.htm) and the cost
of a bed day (non›intensive care) from Unit Costs of
Health and Social Care 2000 9 (table 2). There is no
national database that documents the use of outpatient
services by patients with meningococcal disease,
though most patients will require further treatment or
follow up. We therefore assumed that every patient
attended a first consultation and one follow up
appointment at an average total cost of £246 (NHS
reference costs, equivalent to $350, &403). These costs
were varied in the sensitivity analysis between +/ − 20%
of the base case.
Survivors of meningococcal disease can have a
range of long term sequelae, most commonly hearing
impairment, skin scarring, amputation, and neurologi›
cal disorders. In developed countries 3›15% of
survivors are estimated to have sequelae,10–13 with 7%
assumed in the base case. There are likely to be consid›
erable costs associated with the treatment and rehabili›
tation of survivors with serious sequelae, though there
is no published information detailing these costs in the
Table 1 Estimates of annual incidence of meningococcal group C disease and case
fatality ratios in England and Wales
Age group
(years)
Disease incidence/100 000 Case fatality ratio (%)
High (1998›9) Low (1989›94) Low Medium High
<1 31.53 9.64 4.3 6.2 8.6
1›4 16.09 4.57 4.7 7.1 9.5
5›9 5.77 1.27 1.6 2.8 3.4
10›14 4.97 1.02 5.5 6.6 10.1
15›19 7.92 2.15 14.3 16.5 17.9
20›24 1.89 0.71 8.1 8.0 11.4
25›44 0.67 0.23 12.6 12.8 14.5
45›64 0.77 0.25 13.6 16.4 16.0
>65 0.50 0.23 31.6 36.0 30.6
Overall 2.94 0.84 7.8 9.6 12.6
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United Kingdom. In particular the long term costs to
primary care of subsequent permanent chronic
disability are difficult to estimate. We assumed that 10%
of survivors with sequelae would require lifetime insti›
tutionalised full time care (£21 500 ($30 637, &35 257)
per year).9 Survivors with less severe sequelae were
assumed to require additional health services at an
average cost of £500 (£100 to £1000 in the sensitivity
analysis) per year.
Wider public heath action is recommended after
two or more confirmed or probable cases of meningo›
coccal disease probably caused by the same serogroup
within an institution.14 The primary quantifiable costs
are from vaccination with serogroup C polysaccharide
(about £7 per dose), chemoprophylaxis (about £3 for
600 mg rifampicin every 12 hours for two days),15 and
swabbing of contacts considered at risk (about £10),
with staff costs at about £1 per procedure. We
estimated the average cost of outbreak control per year
from 1996 and 1997 data. There were around 11 out›
breaks per year of serogroup C in school and
preschool settings (J White, personal communication),
with an average of 450 children receiving vaccine and
antibiotics and 100 throat swabs taken at an estimated
cost of £6500 per outbreak. We identified further out›
breaks in community and university settings in the
literature16–20 and, when they were not reported,
estimated costs according to the numbers vaccinated,
given antibiotics, and swabbed. In the base case the
estimated cost per year of outbreak control is
£245 500. This relates to direct health costs only and
not additional external costs incurred (such as
admissions due to false alarms, opportunity costs, costs
to the schools and universities). Because the number
and size of outbreaks cannot be predicted we varied
the cost of outbreak control between +/ − 20% in the
sensitivity analysis. We assumed that outbreaks would
not occur after the start of the vaccination programme,
with savings calculated on the basis that the cohort
would have been at risk of outbreaks in educational
institutions for up to 18 years after the start of the cam›
paign.
Vaccination programme
The UK vaccine schedule recommends three doses for
infants aged under 4 months, two doses for infants
aged 5›12 months, and one dose for children and
young people aged 1›17 years.21 The 2001 UK list price
of the licensed Wyeth meningococcal C vaccine is
£17.95 per dose,15 although bulk purchasing may result
in a lower cost. We assumed the vaccine to cost between
£8 and £18 per dose (£12 in the base case). The total
cost of the television advertising and leaflet campaign
run by the Health Education Authority was £3.5m
(Health Education Authority, personal communica›
tion). By September 2000, 4764 suspected reactions
(including headaches, fever, rash, dizziness, faints,
seizures) had been reported to the Medicines Control
Agency, equivalent to 1:2875 distributed doses, with
anaphylactoid reactions reported at a rate of 1 per
500 000 doses used.22 We assumed that each child with
a reported adverse event was seen by a general
practitioner at a cost of £18 per consultation9 and that
those with anaphylactoid reactions were admitted to
hospital at a cost of £310.9
For each child vaccinated at school the Department
of Health paid a fee of £1 to the relevant NHS trust or
health authority to cover the cost of nursing, adminis›
tration, and consumables. General practitioners
received item of service payments of £6.25 per dose of
vaccine or £4.30 for all but the last dose in a series if
more than one dose was required. These payments
may not accurately reflect the opportunity cost of the
campaign. For example, the campaign involved extra
administration costs for general practitioners and
health authorities, and the normal activities of the
school health service (such as health interviews, health
promotion) were severely disrupted over the duration
of the campaign. To allow for this in the sensitivity
analysis we increased the cost of giving any general
practice based vaccine to £9, to reflect the average cost
for a consultation with a practice nurse (who is likely to
immunise children attending a GP surgery),9 and
increased school based costs from £1 to £3 per dose. In
the base case we added an additional 10% to the
vaccine costs to account for wastage, though there may
be more wastage in general practice than in schools
because of the larger volume of vaccine used in a
school setting. We investigated the effects of this in the
sensitivity analysis.
Early reports in the United Kingdom suggest an
efficacy of 92% (95% confidence interval 65% to 98%)
for toddlers (aged < 2 years) and 97% (77% to 99%) for
teenagers.23 In the base case we assumed vaccine
efficacy to be 95% in 2›12 year olds, with toddlers and
teenagers as above. We estimated vaccine coverage
from routine COVER (cover of vaccination evaluated
rapidly) statistics and four one off data collection exer›
cises. On the basis of these data we assumed coverage
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Fig 1 Percentage of cases in which patients were admitted to
intensive care unit and mean length of stay in hospital and intensive
care, estimated from hospital episode statistics, 1997›8 and 1998›9
Table 2 Unit costs of care and treatment parameters
Parameter Base value (range)
Rate of admission to hospital (%) 100*
Mean cost of intensive care bed/day (£) 1103 (882›1323)†
Mean cost of paediatric intensive care bed/day (£) 1196 (957›1435)†
Mean cost of inpatient day (paediatrics) (£) 310 (248›372)6
Mean cost of inpatient day (general ward) (£) 223 (178›268)6
Admission to intensive care unit (%) 14.9 (9.3›23.6, variable by age)*
Mean length of stay in intensive care (days) 3.5 (2.5›5.9, variable by age)*
Mean length of stay in hospital (days) 7.9 (5.5›17.8, variable by age)*
Mean cost outpatient appointment (1st and follow up) (£) 246 (197›295)†
Cost per general practice consultation (£) 18 (14.40›21.60)6
Cost per practice nurse consultation (£) 9 (7.20›10.80)6
*Hospital episode statistics.
†NHS reference costs.
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to be 89% in under 1 year olds, 82% in 1›4 year olds,24
87% in 5›13 year olds, 83% in 14›15 year olds, and 65%
in 16›17 year olds in full time education (Marie Rush,
personal communication). Limited information is
available on vaccination in 16›17 year olds not in edu›
cation, and we estimated coverage to be 50%.
Results
In the late 1990s the burden of serogroup C meningo›
coccal disease was considerable, with an estimated
1519 cases in 1998›9, of which 1137 occurred in
people aged 0›17 years. There were 72 deaths due to
laboratory confirmed serogroup C disease in this age
group. After adjustment for underascertainment this
figure could be as high as 107 deaths. In the absence of
a meningococcal C vaccination programme, the
annual costs of treating and controlling acute
serogroup C disease in 0›17 year olds is estimated to be
around £3.87m. Inclusion of the costs of treating long
term sequelae increases this to £9.6m (table 3).
The vaccination programme should substantially
reduce the future burden of disease and associated
costs (table 4). The campaign is estimated to prevent
7880 cases and 845 deaths, resulting in nearly 23 000
discounted life years saved over the lifetime of the vac›
cine campaign cohort, given base case assumptions
(table 4). This is estimated to avoid costs of about £29m
present value (base case) in treatment and control. The
total cost of vaccinating the campaign cohort was esti›
mated at £172m at £12/dose (base case), ranging from
£126m at £8 a dose to £241m at £18 a dose.
We estimated the cost per life year saved of the
entire programme to be £6259. The school based cam›
paign is more cost effective than the general
practitioner based campaign, primarily because of the
lower delivery costs per person. Although early
vaccination maximises life years saved, routine vaccina›
tion at 2, 3, and 4 months is the least cost effective
because the cost of giving three doses is substantially
higher. In terms of continued routine vaccination, vac›
cinating children with one dose at 1 year is more cost
effective than vaccinating infants at 2, 3, and 4 months.
However, delaying vaccination could result in up to
200 potentially preventable cases of serogroup C
meningococcal disease in infants under 1 year.
The sensitivity analyses show that the most striking
changes in the cost per life year saved occurred when
the assumptions about incidence of disease and case
fatality ratios were changed (table 5, fig 2). The results
were also sensitive to changes in vaccine cost per dose
and vaccine efficacy. The cost per life year saved is fairly
insensitive to changes in the parameters with the most
uncertainty, such as the cost of treating long term
sequelae. The choice of discount rate is critical to the
outcome (table 6), with the cost per life year saved
increasing as the discount rate increases. Adopting the
UK Treasury recommended discount rate reduces the
cost per life year saved to less than £4000.
In the multivariate sensitivity analysis we fixed the
discount rate at 3% and compared different scenarios
for risk of disease and mortality (fig 2). In the base case
(high incidence, medium case fatality ratio) 95% of the
model simulations resulted in a cost per life year saved
of less than £10 000. If we assumed a high case fatality
ratio and high incidence then 33% of results were
below £5000 per life year saved. If the incidence in the
cohort is low then cost per life year saved is greatly
Table 3 Units and costs of treating and controlling cases of serogroup C meningococcal disease in 0›17 year olds that arise in one
year (base case)
Parameter
Before vaccine After vaccine
Units Cost (£) Units Cost (£)
Cases 1137 248
Deaths 85 21
Inpatient stay in intensive care 1127 bed days 1 347 900 263 bed days 282 300
Inpatient stay on ward 6522 bed days 2 021 900 1486 bed days 460 700
Outpatient follow up 2104 appointments 258 800 496 appointments 61 000
Outbreak costs 11 outbreaks per year 245 550 0 outbreaks 0
Total costs of treating acute meningococcal disease 3 874 250 804 000
Long term costs of treating sequelae* 66 mild 983 000 14 mild 211 500
7 severe 4 708 500 2 severe 1 010 500
Total costs of treating all cases that arise in one year 9 565 750 2 026 000
*Present value of cost of treating cases that arise in one year for the rest of their lifetime, discounted at 3%.
Table 4 Cost per life year saved of meningitis C vaccination programme, discounted to present value (3%)
Component of
campaign
Delivery
method (No of
doses)
Population
(millions)
Cases
avoided
Deaths
avoided
Life
years
saved
Cost of vaccine
campaign
(£m)*
Total cost
savings (£m)
Net cost
(£m)
Cost per
case
avoided
Cost per
life year
saved
0›4 months GP (3) 0.275 365 30 832 13.4 1.2 12.2 33 326 14 630
5›11 months GP (2) 0.384 512 42 1165 12.8 1.7 11.1 21 624 9493
1›4 years GP (1) 2.621 2422 212 5879 42.6 8.3 34.3 14 138 5826
5›17 years School (1) 7.857 4432 539 14 354 96.7 17.3 79.4 17 907 5529
16›17 year olds not in
education
GP (1) 0.654 149 22 569 6.6 0.7 5.9 39 341 10 291
Overall UK campaign
0›17 years
GP and school 11.791 7880 845 22 799 172.0 29.2 142.8 18 112 6259
Alternative strategy (not implemented)
12 months GP (1) 0.659 698 55 1658 10.6 2.4 8.3 11 878 5003
*Cost of Health Education Authority advertising campaign distributed according to population size in each age group.
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increased with 25%, 53%, and 75% of simulations
resulting in a cost per life year saved of more than
£30 000 for high, medium, and low case fatality ratios
respectively.
Discussion
The meningococcal C vaccination campaign has
rapidly and substantially reduced the incidence of
serogroup C meningococcal disease in the targeted
age groups.23 Modelling of the cost effectiveness of the
campaign supports the introduction of the vaccine.
The sensitivity analyses show that assumptions on
the incidence of disease are critical in determining the
cost effectiveness of the campaign. This incidence can›
not be predicted, especially given the variation in and
instability of prevalent meningococcal strains. How›
ever, disease surveillance since the start of the
campaign indicates that incidence of serogroup C dis›
ease has continued to increase in people aged 20›25
years, suggesting that in the absence of vaccination the
incidence of the disease may have also continued to
increase in those aged 0›17 years. This would have
resulted in the vaccine campaign being more cost
effective than we have estimated.
The current schedule of routine infant immunisa›
tion at 2, 3, and 4 months is the most clinically effective
but least cost effective strategy because of the higher
delivery costs and the three dose schedule. Routine
immunisation at 12 months would be more cost effec›
tive but could result in up to 200 preventable cases in
infants each year. The catch up campaign was most
cost effective when delivery was school based rather
than general practice based. School and general prac›
tice components complemented each other because
extra general practice sessions were used to “mop up”
children who missed sessions at school to improve
coverage.
This analysis ignores gains in quality of life, princi›
pally because of a lack of information. Furthermore, we
did not incorporate effects of herd immunity into the
model because of uncertainty over the transmission
dynamics of Neisseria meningitidis. The experience with
Haemophilus influenzae type b (Hib) conjugate vaccina›
tion in the United Kingdom25 (and elsewhere) suggests
that conjugate vaccination reduces carriage. If menin›
gococcal C vaccination reduces transmission of
serogroup C meningococci, the risk of infection for
those who have not been vaccinated would decline.
The net effect of these omissions would be that the
campaign was probably more cost effective than is pre›
sented here.
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What is already known on this topic
The burden of group C meningococcal disease in
England and Wales in the late 1990s was
considerable
In November 1999 the United Kingdom was the
first country to introduce mass vaccination against
group C meningococcal disease
There are no published economic evaluations of
the vaccination campaign
What this study adds
This economic evaluation supports the
introduction of the meningococcal C vaccine
School based vaccination is more cost effective
than routine vaccination of infants because
delivery costs are lower and fewer doses are
required
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